Replimune Reports Fiscal Q2 2027 Results, $57.1 Million Net Loss

What happened

Replimune reported a $57.1 million net loss for its fiscal second quarter ended September 30, 2026, compared with $83.1 million a year earlier. It held $307.8 million in cash and cash equivalents at quarter-end, and TUDRIQEV became commercially available in the U.S. in October for advanced melanoma.

Confirmed

Global impact / market context

The smaller loss and $307.8 million cash balance give Replimune more room to fund the U.S. launch of TUDRIQEV, which means the money needed to promote and supply the newly approved melanoma treatment. Lower research and administrative costs also reduce the cash burned each quarter.

Analyst inference

Investors are shifting focus from research spending to whether Replimune can turn TUDRIQEV interest into revenue. More than 15 institutions had prescribed it, and the company contacted over 70% of its first 200 priority accounts, which means key clinics that could drive early sales.

Analyst inference

What to watch

1. Watch whether TUDRIQEV prescriptions and deliveries grow beyond the more than 15 institutions that had prescribed it by the announcement, since each new prescribing site can add product demand and revenue. Confirmed
2. Track how quickly Replimune converts its first 200 priority accounts into repeat prescribers, because adoption at these target clinics would show whether launch spending is producing sales. Proposed
3. Monitor research and administrative costs against the $307.8 million cash balance to judge how many quarters of launch funding remain, since a wider loss would shorten that runway. Analyst inference

Evidence

• Original source link unavailable